A safety and efficacy study to evaluate the sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.

Trial Profile

A safety and efficacy study to evaluate the sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Nov 2015 New trial record
    • 01 Mar 2014 Results published at Hepato-Gastroenterology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top